Vertex Pharmaceuticals Inc.'s unveiling last week of the Phase III program for the protease inhibitor telaprevir - the latest volley in the battle for a better hepatitis C virus therapy - brought cheers, muted somewhat by the inclusion of a 48-week treatment study, added to the larger test lasting half that long. (BioWorld Financial Watch)